EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
dc.contributor.author | Smolen, JS | en_US |
dc.contributor.author | Landewe, RBM | en_US |
dc.contributor.author | Bergstra, SA | en_US |
dc.contributor.author | Kerschbaumer, A | en_US |
dc.contributor.author | Sepriano, A | en_US |
dc.contributor.author | Aletaha, D | en_US |
dc.contributor.author | Caporali, R | en_US |
dc.contributor.author | Edwards, CJ | en_US |
dc.contributor.author | Hyrich, KL | en_US |
dc.contributor.author | Pope, JE | en_US |
dc.contributor.author | de Souza, S | en_US |
dc.contributor.author | Stamm, TA | en_US |
dc.contributor.author | Takeuchi, T | en_US |
dc.contributor.author | Verschueren, P | en_US |
dc.contributor.author | Winthrop, KL | en_US |
dc.contributor.author | Balsa, A | en_US |
dc.contributor.author | Bathon, JM | en_US |
dc.contributor.author | Buch, MH | en_US |
dc.contributor.author | Burmester, GR | en_US |
dc.contributor.author | Buttgereit, F | en_US |
dc.contributor.author | Cardiel, MH | en_US |
dc.contributor.author | Chatzidionysiou, K | en_US |
dc.contributor.author | Codreanu, C | en_US |
dc.contributor.author | Cutolo, M | en_US |
dc.contributor.author | den Broeder, AA | en_US |
dc.contributor.author | El Aoufy, K | en_US |
dc.contributor.author | Finckh, A | en_US |
dc.contributor.author | Fonseca, JE | en_US |
dc.contributor.author | Gottenberg, J-E | en_US |
dc.contributor.author | Haavardsholm, EA | en_US |
dc.contributor.author | Iagnocco, A | en_US |
dc.contributor.author | Lauper, K | en_US |
dc.contributor.author | Li, Z | en_US |
dc.contributor.author | McInnes, IB | en_US |
dc.contributor.author | Mysler, EF | en_US |
dc.contributor.author | Nash, P | en_US |
dc.contributor.author | Poor, G | en_US |
dc.contributor.author | Ristic, GG | en_US |
dc.contributor.author | Rivellese, F | en_US |
dc.contributor.author | Rubbert-Roth, A | en_US |
dc.contributor.author | Schulze-Koops, H | en_US |
dc.contributor.author | Stoilov, N | en_US |
dc.contributor.author | Strangfeld, A | en_US |
dc.contributor.author | van der Helm-van Mil, A | en_US |
dc.contributor.author | van Duuren, E | en_US |
dc.contributor.author | Vliet Vlieland, TPM | en_US |
dc.contributor.author | Westhovens, R | en_US |
dc.contributor.author | van der Heijde, D | en_US |
dc.date.accessioned | 2023-01-12T13:43:34Z | |
dc.date.available | 2022-10-21 | en_US |
dc.date.issued | 2023 | en_US |
dc.identifier.issn | 0003-4967 | en_US |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/83757 | |
dc.format.extent | 3 - 18 | en_US |
dc.relation.ispartof | ANNALS OF THE RHEUMATIC DISEASES | en_US |
dc.subject | Arthritis | en_US |
dc.subject | Rheumatoid | en_US |
dc.subject | Antirheumatic Agents | en_US |
dc.subject | Biological Therapy | en_US |
dc.title | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update | en_US |
dc.type | Article | |
dc.identifier.doi | 10.1136/ard-2022-223356 | en_US |
pubs.author-url | https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000885543600001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a | en_US |
pubs.issue | 1 | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 82 | en_US |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |